Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 117

2.

Laser interstitial thermal therapy for palliative ablation of a chordoma metastasis to the spine: case report.

Williams BJ, Karas PJ, Rao G, Rhines LD, Tatsui CE.

J Neurosurg Spine. 2017 Mar 31:1-3. doi: 10.3171/2016.11.SPINE16897. [Epub ahead of print]

PMID:
28362211
3.

Reply to Freyschlag et al.

Wefel JS, Noll KR, Rao G, Cahill DP.

Neuro Oncol. 2017 Apr 1;19(4):598-599. doi: 10.1093/neuonc/now296. No abstract available.

PMID:
28339696
4.

Image guidance based on MRI for spinal interstitial laser thermotherapy: technical aspects and accuracy.

Tatsui CE, Nascimento CNG, Suki D, Amini B, Li J, Ghia AJ, Thomas JG, Stafford RJ, Rhines LD, Cata JP, Kumar AJ, Rao G.

J Neurosurg Spine. 2017 May;26(5):605-612. doi: 10.3171/2016.9.SPINE16475. Epub 2017 Feb 10.

PMID:
28186470
5.

Spinal Laser Interstitial Thermal Therapy: A Novel Alternative to Surgery for Metastatic Epidural Spinal Cord Compression.

Tatsui CE, Lee SH, Amini B, Rao G, Suki D, Oro M, Brown PD, Ghia AJ, Bhavsar S, Popat K, Rhines LD, Stafford RJ, Li J.

Neurosurgery. 2016 Dec;79 Suppl 1:S73-S82.

PMID:
27861327
6.

The effect of IDH1 mutation on the structural connectome in malignant astrocytoma.

Kesler SR, Noll K, Cahill DP, Rao G, Wefel JS.

J Neurooncol. 2017 Feb;131(3):565-574. doi: 10.1007/s11060-016-2328-1. Epub 2016 Nov 15.

PMID:
27848136
7.

The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications.

Hu J, Yan J, Rao G, Latha K, Overwijk WW, Heimberger AB, Li S.

Int Rev Immunol. 2016 Jul 3;35(4):325-339. Epub 2014 Sep 26.

PMID:
25259408
8.

Laser interstitial thermal therapy for newly diagnosed and recurrent glioblastoma.

Thomas JG, Rao G, Kew Y, Prabhu SS.

Neurosurg Focus. 2016 Oct;41(4):E12.

PMID:
27690657
9.

Percutaneous surgery for treatment of epidural spinal cord compression and spinal instability: technical note.

Tatsui CE, Belsuzarri TA, Oro M, Rhines LD, Li J, Ghia AJ, Amini B, Espinoza H, Brown PD, Rao G.

Neurosurg Focus. 2016 Oct;41(4):E2.

PMID:
27690655
10.

Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection.

Wefel JS, Noll KR, Rao G, Cahill DP.

Neuro Oncol. 2016 Dec;18(12):1656-1663. Epub 2016 Aug 30.

PMID:
27576872
11.

Tipping a favorable CNS intratumoral immune response using immune stimulation combined with inhibition of tumor-mediated immune suppression.

Kong LY, Wei J, Fuller GN, Schrand B, Gabrusiewicz K, Zhou S, Rao G, Calin G, Gilboa E, Heimberger AB.

Oncoimmunology. 2015 Dec 21;5(5):e1117739. doi: 10.1080/2162402X.2015.1117739. eCollection 2016 May.

12.

DEMARCATE: Density-based magnetic resonance image clustering for assessing tumor heterogeneity in cancer.

Saha A, Banerjee S, Kurtek S, Narang S, Lee J, Rao G, Martinez J, Bharath K, Rao AU, Baladandayuthapani V.

Neuroimage Clin. 2016 May 27;12:132-43. doi: 10.1016/j.nicl.2016.05.012. eCollection 2016.

13.

215 Postoperative Stereotactic Radiosurgery vs Observation for Completely Resected Brain Metastases: Results of a Prospective Randomized Study.

Rao G, Ahmed S, Hess K, Mahajan A.

Neurosurgery. 2016 Aug;63 Suppl 1:184. doi: 10.1227/01.neu.0000489784.83922.17.

PMID:
27399494
14.

Analysis of the inhibitors of apoptosis identifies BIRC3 as a facilitator of malignant progression in glioma.

Gressot LV, Doucette T, Yang Y, Fuller GN, Manyam G, Rao A, Latha K, Rao G.

Oncotarget. 2017 Feb 21;8(8):12695-12704. doi: 10.18632/oncotarget.8657.

15.
16.

Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype.

Gabrusiewicz K, Rodriguez B, Wei J, Hashimoto Y, Healy LM, Maiti SN, Thomas G, Zhou S, Wang Q, Elakkad A, Liebelt BD, Yaghi NK, Ezhilarasan R, Huang N, Weinberg JS, Prabhu SS, Rao G, Sawaya R, Langford LA, Bruner JM, Fuller GN, Bar-Or A, Li W, Colen RR, Curran MA, Bhat KP, Antel JP, Cooper LJ, Sulman EP, Heimberger AB.

JCI Insight. 2016;1(2). pii: e85841. Epub 2016 Feb 25.

17.

Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.

Shingu T, Holmes L, Henry V, Wang Q, Latha K, Gururaj AE, Gibson LA, Doucette T, Lang FF, Rao G, Yuan L, Sulman EP, Farrell NP, Priebe W, Hess KR, Wang YA, Hu J, Bögler O.

J Transl Med. 2016 Feb 9;14:46. doi: 10.1186/s12967-016-0803-2.

18.
19.

Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.

Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, Rao AA, Grifford M, Cherniack AD, Zhang H, Poisson L, Carlotti CG Jr, Tirapelli DP, Rao A, Mikkelsen T, Lau CC, Yung WK, Rabadan R, Huse J, Brat DJ, Lehman NL, Barnholtz-Sloan JS, Zheng S, Hess K, Rao G, Meyerson M, Beroukhim R, Cooper L, Akbani R, Wrensch M, Haussler D, Aldape KD, Laird PW, Gutmann DH; TCGA Research Network., Noushmehr H, Iavarone A, Verhaak RG.

Cell. 2016 Jan 28;164(3):550-63. doi: 10.1016/j.cell.2015.12.028.

20.

Evaluation of tumor-derived MRI-texture features for discrimination of molecular subtypes and prediction of 12-month survival status in glioblastoma.

Yang D, Rao G, Martinez J, Veeraraghavan A, Rao A.

Med Phys. 2015 Nov;42(11):6725-35. doi: 10.1118/1.4934373.

Supplemental Content

Loading ...
Support Center